Bausch + Lomb Vision-Correction Surgery Platform Approved in U.S. by FDA
Provided by
Dow Jones
By Adriano Marchese
Bausch + Lomb said Monday that its laser-assisted vision correction surgery platform to treat nearsightedness was approved by the U.S. Food and Drug Administration.
The Canadian eye-health company said the FDA has approved the Teneo Excimer Laser Platform for laser-assisted in situ keratomileusis, also known as Lasik, vision correction surgery for myopia and myopic astigmatism.
Bausch + Lomb said that Teneo has been adopted in more than 50 countries around the world.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
January 08, 2024 07:26 ET (12:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
United States